Hikma Pharmaceuticals

Hikma Pharmaceuticals plc operates as a leading global generic and specialty pharmaceutical company with a strong focus on injectables and oral generics. It has over $3 billion in annual revenue and more than $700 million in operating income as of FY2024. The company supplies over 800 products across North America, MENA and Europe. Its portfolio includes small molecule generics/branded drugs and biosimilars for major therapeutic areas such as oncology/cancer care and infectious diseases. Recent clinical/commercial highlights include the launch of biosimilar rituximab/trastuzumab in MENA through Celltrion partnerships; acquisition of Novugen’s FDA-approved ANDA for trametinib; exclusive licensing deals to bring innovative oncology treatments to the MENA region; continued expansion via acquisitions in Europe/MENA/US markets.[2][6]